FTSV / Forty Seven, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

FTSV / Forty Seven, Inc. 15-12B - - 15-12B

15-12B 1 a20-1573211512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38554 Forty Seven, Inc. (Exact name

FTSV / Forty Seven, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P104 (CUSIP Number) March 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

FTSV / Forty Seven, Inc. S-8 POS - - S-8 POS

As filed with the Securities and Exchange Commission on April 7, 2020 Registration No.

FTSV / Forty Seven, Inc. POSASR - - POSASR

POSASR 1 a20-149804posasr.htm POSASR As filed with the Securities and Exchange Commission on April 7, 2020 Registration No. 333-235877 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-235877 UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact name of Registrant as specified in its charter) Delawa

FTSV / Forty Seven, Inc. POS AM - - POS AM

POS AM 1 a20-149803posam.htm POS AM As filed with the Securities and Exchange Commission on April 7, 2020 Registration No. 333-232498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-232498 UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact name of Registrant as specified in its charter) Delawar

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2020 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission File Nu

AMENDED AND RESTATED BYLAWS FORTY SEVEN, INC. A Delaware Corporation Effective April 7, 2020

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FORTY SEVEN, INC. A Delaware Corporation Effective April 7, 2020 TABLE OF CONTENTS Page ARTICLE I OFFICES Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings 1 Section 2. Annual Meetings 2 Section 3. Special Meetings 2 Section 4. Notice 2 Section 5. Adjournments and Postponements 3 Sec

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A 1 a20-116279sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHAR

GILD / Gilead Sciences, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A 1 a20-1162012sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offer

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION FORTY SEVEN, INC.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORTY SEVEN, INC. FIRST: The name of the Corporation is Forty Seven, Inc. (the “Corporation”). SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Wilmington, County of New Castle, Delaware, 19801. The name of its registered agent at that address is The Corporation Trust Com

FTSV / Forty Seven, Inc. S-8 POS - - S-8 POS

S-8 POS 1 a20-149802s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on April 7, 2020 Registration No. 333-225958 Registration No. 333-230585 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-225958 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-230585 UN

FTSV / Forty Seven, Inc. POS462B - - POS462B

As filed with the Securities and Exchange Commission on April 7, 2020 Registration No.

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A 1 a20-116278sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHAR

GILD / Gilead Sciences, Inc. SC TO-T/A - - SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Sha

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A 1 a20-116277sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHAR

GILEAD ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR FORTY SEVEN TENDER OFFER

Exhibit (a)(5)(M) CONTACTS: Douglas Maffei, PhD, Investors (650) 522-2739 Amy Flood, Media (650) 522-5643 For Immediate Release GILEAD ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR FORTY SEVEN TENDER OFFER Foster City, Calif.

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 34983P 104

GILD / Gilead Sciences, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A 1 a20-1162010sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offer

Description of the Registrant’s Securities

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, $0.0001 par value per share (“Common Stock”) of Forty Seven, Inc. (the “Company,” “we,” “our,” or “us”) , which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934

Annual Report - 10-K

10-K 1 ftsv-10k20191231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38554 FORTY SEVEN, IN

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A 1 a20-116275sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHAR

GILD / Gilead Sciences, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A 1 a20-116209sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offero

FTSV / Forty Seven, Inc. / Lightspeed Venture Partners X, L.p. - SC 13D/A Activist Investment

SC 13D/A 1 a20-127251sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P 104 (CUSIP Number) Andrew Moley Lightspeed Venture Partners 2200 Sand Hill Road Menlo Park, CA 94025 Telephone: (650) 234-8300

FTSV / Forty Seven, Inc. SC 14D9/A - - SC 14D9/A

SC 14D9/A 1 a20-116274sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHAR

GILD / Gilead Sciences, Inc. SC TO-T/A - - SC TO-T/A

SC TO-T/A 1 a20-116208sctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly-owned subsidiary of GILEAD SCIENCES, INC. (Names of Filing Persons (Offero

Offer To Purchase For Cash All Outstanding Shares of Common Stock of FORTY SEVEN, INC. a Delaware corporation at $95.50 NET PER SHARE Pursuant to the Offer to Purchase dated March 10, 2020 by TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD

Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of FORTY SEVEN, INC.

FTSV / Forty Seven, Inc. SC 14D9 - - SC 14D9

SC 14D9 1 a2240913zsc14d9.htm SC 14D9 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Forty Seven, Inc. (Name of Subject Company) Forty Seven, Inc. (Name of Person

LETTER OF TRANSMITTAL To Tender Shares of Common Stock of FORTY SEVEN, INC. a Delaware corporation at $95.50 NET PER SHARE Pursuant to the Offer to Purchase Dated March 10, 2020 by TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, I

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of FORTY SEVEN, INC.

GILD / Gilead Sciences, Inc. SC TO-T - - SC TO-T

SC TO-T 1 a2240910zscto-t.htm SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIE

NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of FORTY SEVEN, INC. a Delaware corporation at $95.50 NET PER SHARE Pursuant to the Offer to Purchase dated March 10, 2020 by TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of FORTY SEVEN, INC.

Offer To Purchase For Cash All Outstanding Shares of Common Stock of FORTY SEVEN, INC. a Delaware corporation at $95.50 NET PER SHARE Pursuant to the Offer to Purchase dated March 10, 2020 by TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of FORTY SEVEN, INC.

This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase, dated March 10, 2020, and the related Letter of Transmi

Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below).

Offer to Purchase All Outstanding Shares of Common Stock of FORTY SEVEN, INC. At $95.50 Net Per Share in Cash by TORO MERGER SUB, INC. a wholly owned subsidiary of GILEAD SCIENCES, INC. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER

QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of FORTY SEVEN, INC.

GILEAD SCIENCES, INC. MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT

Exhibit (e)(2) Confidential GILEAD SCIENCES, INC. MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Mutual Confidential Disclosure Agreement (“Agreement”) is made effective as of January 7, 2020 (the “Effective Date”) by and between Forty Seven, Inc., a Delaware corporation with offices at 1490 O’Brien Drive, Suite A, Menlo Park, California 94025, USA (“Company”), and Gilead Sciences, Inc., a Delaware

Employee Q & A’s March 9, 2020 1

Exhibit 99.1 Employee Q & A’s March 9, 2020 1 Forward-Looking Statements This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are

FTSV / Forty Seven, Inc. SC14D9C - - SC14D9C

SC14D9C 1 a20-116273sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTY SEVEN, INC. (Name of Subject Company) FORTY SEVEN, INC. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of S

Tax Considerations for Forty Seven Merger Scott Mathews [email protected] (408) 558-7605 Tax Senior Manager

Exhibit 99.2 Tax Considerations for Forty Seven Merger Scott Mathews [email protected] (408) 558-7605 Tax Senior Manager Forward-Looking Statements This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject to risks, uncerta

GILD / Gilead Sciences, Inc. SC TO-C - - SC TO-C

SC TO-C 1 a20-112534sctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securitie

Gilead Tweet (@GileadSciences), March 2, 2020

Exhibit 99.3 Gilead Tweet (@GileadSciences), March 2, 2020 @FortySevenInc shares our commitment to advancing therapeutics in areas of unmet medical need. Read more from our Chairman and CEO, Daniel O’Day, about how this collaboration will help to create a healthier, better world for everyone. #CreatingPossible

Gilead Sciences, Inc.

Exhibit 99.1 Corrected Transcript 02-Mar-2020 Gilead Sciences, Inc. (GILD) Cowen Health Care Conference Total Pages: 14 1-877-FACTSET www.callstreet.com Copyright © 2001-2020 FactSet CallStreet, LLC Gilead Sciences, Inc. (GILD) Corrected Transcript Cowen Health Care Conference 02-Mar-2020 CORPORATE PARTICIPANTS Johanna Mercier Chief Commercial Officer, Gilead Sciences, Inc. Merdad V. Parsey Chief

Innovation and Growth in Immuno-Oncology

Exhibit 99.2 Innovation and Growth in Immuno-Oncology By Daniel O’Day This is an exciting day for Gilead. We have just signed an agreement to buy Forty Seven, a Bay Area company that has made highly promising progress in a novel area of immuno-oncology. The company’s lead molecule, magrolimab is in clinical development and has shown the potential to be a first-in-class treatment. Acquiring Forty S

GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION – Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

EX-99.1 3 tm2011253d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CONTACTS: Gilead Sciences, Inc. Forty Seven, Inc. Douglas Maffei, PhD, Investors Hannah Deresiewicz, Investors (650) 522-2739 (212) 362-1200 Amy Flood, Media Ann Rhoads, Investors (650) 522-5643 (650) 352-4853 Sarah Plumridge, Media (312) 506-5200 GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION – Gilead Gains Forty Seven’s Investigational Im

Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject

EX-99.6 All Hands Meeting March 2, 2020 Exhibit 99.6 Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements of historical fa

Gilead to Acquire FortySeven March 2, 2020

Exhibit 99.1 Gilead to Acquire FortySeven March 2, 2020 This communication contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Forty Seven and the acquisition of Forty Seven by Gilead that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K 1 d890968d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2020 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorpora

AGREEMENT AND PLAN OF MERGER FORTY SEVEN, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and TORO MERGER SUB, INC., a Delaware corporation Dated as of March 1, 2020

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: FORTY SEVEN, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and TORO MERGER SUB, INC., a Delaware corporation Dated as of March 1, 2020 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 4 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser into the Company 6 2.2 Effect of the Merger 6 2.3

Email to Gilead Operating Group

Exhibit 99.4 Email to Gilead Operating Group This morning, we announced that Gilead will acquire Forty Seven, a clinical-stage immuno-oncology company, in a $4.9 billion agreement. We’ve included some key messages below and attached an FAQ to help you answer questions you may receive from your teams. Please do not forward this email — it is meant to help guide conversation. *** Key Talking Points

EX-99.5

EX-99.5 Exhibit 99.5 Hi All: To follow up with our announcement this morning, and just prior to our all-company lunch, I would like to share with you a note from Daniel O’Day, CEO of Gilead. Dan is a remarkable man that possesses and displays our core values of passion to action, being bold, yet humble, and being inquisitive. I look forward to introducing Dan to you tomorrow when he comes to the o

LinkedIn: Forty Seven Post, March 2, 2020

EX-99.9 10 d889366dex999.htm EX-99.9 Exhibit 99.9 LinkedIn: Forty Seven Post, March 2, 2020 Gilead to Acquire Forty Seven for $4.9 Billion: https://lnkd.in/gV8M9wj

GILD / Gilead Sciences, Inc. SC TO-C - - SC TO-C

SC TO-C 1 tm2011253d38k.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2020 Gilead Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation)

Hello all:

EX-99.4 5 d889366dex994.htm EX-99.4 Exhibit 99.4 Hello all: Today is a transformative day for Forty Seven. A few minutes ago, we announced that Gilead intends to acquire Forty Seven for $95.50 per share, which represents an equity value for the entire company of approximately $4.9 billion on a fully-diluted basis. Gilead’s offer is a testament to the value you have all created through your unrelen

Gilead Tweet (@GileadSciences), March 2, 2020

Exhibit 99.8 Gilead Tweet (@GileadSciences), March 2, 2020 Today we announced that we will acquire @FortySevenInc, a clinical-stage immuno-oncology company. This transaction supports our strategic focus in oncology and gives access to a potential new first-in-class program. Read more: http://bit.ly/2wl2Jhk.

FTSV / Forty Seven, Inc. SC14D9C - - SC14D9C

SC14D9C 1 d889366dsc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTY SEVEN, INC. (Name of Subject Company) FORTY SEVEN, INC. (Name of Person Filing Statement) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Sec

Forty Seven Tweet (@FortySevenInc), March 2, 2020

EX-99.8 9 d889366dex998.htm EX-99.8 Exhibit 99.8 Forty Seven Tweet (@FortySevenInc), March 2, 2020 Gilead to Acquire Forty Seven for $4.9 Billion: https://t.co/vihBBqhn8R?amp=1

Email to Forty Seven’s Employees

Exhibit 99.6 Email to Forty Seven’s Employees Hi All: To follow up with our announcement this morning, and just prior to our all-company lunch, I would like to share with you a note from Daniel O’Day, CEO of Gilead. Dan is a remarkable man that possesses and displays our core values of passion to action, being bold, yet humble, and being inquisitive. I look forward to introducing Dan to you tomorr

Gilead and Forty Seven Merger Agreement

Exhibit 99.7 Gilead and Forty Seven Merger Agreement Q: What was announced on March 2, 2020? Gilead announced plans to acquire Forty Seven for approximately $4.9 billion. The agreement was unanimously approved by both boards of directors and is expected to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions. The acquisition will be struct

EXTERNAL Q&A

EX-99.2 3 d889366dex992.htm EX-99.2 Exhibit 99.2 EXTERNAL Q&A What role will your executive team have after the Merger? Gilead looks forward to working with the highly experienced team at Forty Seven to help patients with some of the most challenging forms of cancer. We will provide more details on matters such as this as we move through this process. What is the status of your ongoing programs? A

Gilead and Forty Seven Merger Agreement

EX-99.3 Exhibit 99.3 Gilead and Forty Seven Merger Agreement Q: What was announced on March 2, 2020? Gilead announced plans to acquire Forty Seven for approximately $4.9 billion. The agreement was unanimously approved by both boards of directors and is expected to close during the second quarter of 2020, subject to regulatory approvals and other customary closing conditions. The acquisition will b

Frequently Asked Questions Sent to Gilead Operating Group

Exhibit 99.5 Frequently Asked Questions Sent to Gilead Operating Group Frequently Asked Questions For Internal Use Only, Not for Distribution · What was announced on March 2, 2020? Gilead announced plans to acquire Forty Seven for $4.9 billion. The agreement was unanimously approved by both boards of directors and is expected to close in the second quarter. · What is the rationale for this deal? T

Email to Wall Street Community

EX-99.7 Exhibit 99.7 Email to Wall Street Community SUBJECT: Gilead to Acquire Forty Seven in Cash Transaction Valued at $4.9B [Name]: Earlier this morning, we announced that we have entered into an agreement to be acquired by Gilead Sciences, Inc. (Nasdaq:GILD) for $95.50 per share, which represents an equity value for Forty Seven of approximately $4.9B on a fully-diluted basis. The press release

GILD / Gilead Sciences, Inc. SC TO-C - - SC TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 FORTY SEVEN, INC. (Name of Subject Company (Issuer)) TORO MERGER SUB, INC. (Names of Filing Persons (Offeror)) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 34983P104 (Cusip Number of Class of

Email to Gilead Employees

Exhibit 99.3 Email to Gilead Employees To All Employees, Today we are announcing an important new acquisition that will build on our expertise in oncology and add a potentially transformative medicine to our clinical pipeline. The agreement to acquire Forty Seven aligns with our strategic focus on immuno-oncology and our commitment to expanding innovation with the highest quality science. Forty Se

INTERNAL Q&A

EX-99.1 Exhibit 99.1 INTERNAL Q&A General Transaction Information Q: What was announced? Forty Seven has entered into a definitive merger agreement to be acquired by Gilead for $95.50 per share, or approximately $4.9 billion in cash. We believe that this transaction represents the best step forward for our company. Q: Who is Gilead? What do they do? Gilead is a science-focused biopharmaceutical co

GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION – Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma

EX-99.1 Exhibit 99.1 CONTACTS: Gilead Sciences, Inc. Forty Seven, Inc. Douglas Maffei, PhD, Investors Hannah Deresiewicz, Investors (650) 522-2739 (212) 362-1200 Amy Flood, Media Ann Rhoads, Investors (650) 522-5643 (650) 352-4853 Sarah Plumridge, Media (312) 506-5200 GILEAD TO ACQUIRE FORTY SEVEN FOR $4.9 BILLION – Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Cli

AGREEMENT AND PLAN OF MERGER FORTY SEVEN, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and TORO MERGER SUB, INC., a Delaware corporation Dated as of March 1, 2020 Table of Contents Section 1 THE OFFER

EX-2.1 2 tm2011253d3ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 CONFIDENTIAL EXECUTION COPY AGREEMENT AND PLAN OF MERGER among: FORTY SEVEN, INC., a Delaware corporation; GILEAD SCIENCES, INC., a Delaware corporation; and TORO MERGER SUB, INC., a Delaware corporation Dated as of March 1, 2020 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 4 Section 2 MERGER TRANSACTION 2.1 Merger

Investor Call Transcript

EX-99.2 3 a20-112531ex99d2.htm EX-99.2 Exhibit 99.2 Investor Call Transcript [0:00:00] Shannon: Ladies and gentlemen, thank you for standing by and welcome to the Gilead Sciences conference call. At this time, all participant lines are in listen-only mode. After the speakers’ presentation, there’ll be a question and answer session. To ask a question during the session, you will need to press star,

FTSV / Forty Seven, Inc. / Redmile Group, LLC - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Forty Seven, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 34983P104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Forty Seven, Inc., wh

FTSV / Forty Seven, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing unde

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 5 d845416dex48.htm EX-4.8 Exhibit 4.8 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] o

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

8-K 1 d868270d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2020 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorp

FTSV / Forty Seven, Inc. S-3ASR - - S-3ASR

S-3ASR Table of Contents As filed with the U.S. Securities and Exchange Commission on January 10, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact name of Registrant as specified in its charter) Delaware 47-4065674 (State or other jurisdiction of (I.R.S. Emplo

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the law

Forty Seven, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement

EX-1.1 Exhibit 1.1 Forty Seven, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement January 10, 2020 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Forty Seven, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issuanc

Forty Seven Announces 2020 Strategic Priorities and Expected Milestones — Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 — — Updated Data from

EX-99.1 Exhibit 99.1 Forty Seven Announces 2020 Strategic Priorities and Expected Milestones — Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 — — Updated Data from Ongoing Phase 1b Trial in Higher-Risk MDS and AML Expected Mid-Year 2020 — — Initial Data from Phase 3 Trial in DLBCL Expected i

CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.0001 per share $100,000,000 $12,980

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-235877 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 d856445d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2020 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorp

Form of Indenture.

EX-4.4 2 d845416dex44.htm EX-4.4 Exhibit 4.4 FORTY SEVEN, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and

FTSV / Forty Seven, Inc. / SUTTER HILL VENTURES - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P 104 (CUSIP Number) Robert Yin Sutter Hill Ventures 755 Page Mill Rd., Suite #A-200 Palo Alto, CA 94304 650-493-5600 (Name, Address and Telephone Number of Person Author

4,860,000 Shares FORTY SEVEN, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENT

EX-1.1 Exhibit 1.1 EXECUTION VERSION 4,860,000 Shares FORTY SEVEN, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENT December 11, 2019 December 11, 2019 Morgan Stanley & Co. LLC Credit Suisse Securities (USA) LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Credit Suisse Securities (USA) LLC 11 Madison Avenue New York, New York 10010 Ladies and Gentl

Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K 1 d843701d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incor

4,860,000 Shares COMMON STOCK

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-232498 and 333-235458 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2019) 4,860,000 Shares COMMON STOCK We are offering 4,860,000 shares of our common stock pursuant to this prospectus supplement.

FTSV / Forty Seven, Inc. S-3MEF - - S-3MEF

S-3MEF 1 d841396ds3mef.htm S-3MEF As filed with the U.S. Securities and Exchange Commission on December 11, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4065674 (State or Other Jurisdiction of Inc

$140,000,000 COMMON STOCK

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232498 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any jurisdiction whe

EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between FORTY SEVEN, INC. ONO PHARMACEUTICAL CO., LTD.

Exhibit 10.1 [***] = Certain information contained in this document, marked by brackets, has been omitted because it is both not material and would be competitively harmful if publicly disclosed. Execution Version Confidential EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT by and between FORTY SEVEN, INC. and ONO PHARMACEUTICAL CO., LTD. Execution Version Confidential TABLE OF CONTENTS Page ARTICLE

FTSV / Forty Seven, Inc. 10-Q - Quarterly Report - 10-Q

10-Q 1 ftsv-10q20190930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 ftsv-8k20191112.htm FTSV 8K EARNINGS RELEASE Q3 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (St

Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights -- On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 – -- Entered into Collaboration with bluebird bio to Evaluate Ant

Exhibit 99.1 Helping Patients Defeat Their Cancer Forty Seven, Inc. Reports Third Quarter 2019 Financial Results and Recent Business Highlights - On-Track to Initiate Potential Registration-Enabling Trials in MDS and DLBCL in 1Q 2020 – - Entered into Collaboration with bluebird bio to Evaluate Antibody-Based Conditioning Regimen in Combination with LentiGlobin – - Management to Host Conference Cal

Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights -- Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings -- -- Received FDA Feedback Suggesting Single-Arm Pivotal Trials May

Exhibit 99.1 Forty Seven Inc. Reports Second Quarter 2019 Financial Results and Recent Business Highlights - Presented Updated Data for 5F9 in Four Patient Populations at ASCO and EHA Meetings - - Received FDA Feedback Suggesting Single-Arm Pivotal Trials May Support Registration in MDS and DLBCL - - Entered Exclusive Licensing Agreement with Ono Pharmaceutical to Develop and Commercialize 5F9 in

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission File

FTSV / Forty Seven, Inc. 10-Q - Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38554 FORTY SEVEN, INC.

FTSV / Forty Seven, Inc. / Lightspeed Venture Partners X, L.p. - SC 13D/A Activist Investment

SC 13D/A 1 a19-169321sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P 104 (CUSIP Number) Andrew Moley Lightspeed Venture Partners 2200 Sand Hill Road Menlo Park, CA 94025 Telephone: (650) 234-8300

Financial Statements and Exhibits, Other Events

8-K 1 d779646d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorpora

9,375,000 Shares FORTY SEVEN, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENT

EX-1.1 Exhibit 1.1 EXECUTION VERSION 9,375,000 Shares FORTY SEVEN, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENT July 17, 2019 July 17, 2019 Morgan Stanley & Co. LLC Credit Suisse Securities (USA) LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Credit Suisse Securities (USA) LLC 11 Madison Avenue New York, New York 10010 Ladies and Gentlemen: Fo

9,375,000 Shares COMMON STOCK

424B5 1 d65661d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232498 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2019) 9,375,000 Shares COMMON STOCK We are offering 9,375,000 shares of our common stock pursuant to this prospectus supplement. Our common stock is listed on The Nasdaq Global Select Market under the symbol “FTSV.” On July 17, 2019, the

$75,000,000 COMMON STOCK

424B5 1 d65661d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-232498 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these secu

FTSV / Forty Seven, Inc. S-3/A - - S-3/A

S-3/A 1 d771854ds3a.htm S-3/A Table of Contents As filed with the U.S. Securities and Exchange Commission on July 12, 2019 Registration No. 333-232498 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact name of Registrant as specified in its charter) Delaware 47-4065674

Entry into a Material Definitive Agreement

8-K 1 d744243d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorpora

FTSV / Forty Seven, Inc. CORRESP - -

CORRESP 1 filename1.htm FORTY SEVEN, INC. 1490 O’Brien Drive, Suite A Menlo Park, California 94025 July 10, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Ms. Suzanne Hayes, Assistant Director Ms. Ada Sarmento, Attorney Advisor RE: Forty Seven, Inc. Registration Statement on Form S-3 Filed July 1

Form of Indenture.

EX-4.4 Exhibit 4.4 FORTY SEVEN, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 Se

Forty Seven, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement

Exhibit 1.2 Forty Seven, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement July 1, 2019 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Forty Seven, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issuance and Sale

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

EX-4.7 Exhibit 4.7 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing unde

Form of Debt Securities Warrant Agreement and Warrant Certificate.

EX-4.8 Exhibit 4.8 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing unde

Form of Common Stock Warrant Agreement and Warrant Certificate.

EX-4.6 Exhibit 4.6 FORTY SEVEN, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF FORTY SEVEN, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between FORTY SEVEN, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the law

FTSV / Forty Seven, Inc. S-3 - - S-3

Table of Contents As filed with the U.S. Securities and Exchange Commission on July 1, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact name of Registrant as specified in its charter) Delaware 47-4065674 (State or other jurisdiction of (I.R.S. Employer incorpo

Submission of Matters to a Vote of Security Holders

8-K 1 d756638d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorpora

additional materials

DEFA14A 1 d752743ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi

Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights -- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in r/r NHL to be Presented at EHA and ICML in June -- – Updated Data from Phase 1b

EX-99.1 2 ftsv-ex9916.htm EX-99.1 Exhibit 99.1 Forty Seven Inc. Reports First Quarter 2019 Financial Results and Recent Business Highlights - Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in r/r NHL to be Presented at EHA and ICML in June - – Updated Data from Phase 1b Trial of 5F9 as Monotherapy and in Combination with Azacitidine in AML and MDS to be Presented at ASCO a

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 ftsv-8k20190513.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incor

FTSV / Forty Seven, Inc. 10-Q Quarterly Report 10-Q

10-Q 1 ftsv-10q20190331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

8-K 1 d709490d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorpor

FIRST AMENDMENT TO LEASE 1490 O’Brien Drive, Suite A, B and E Menlo Park, California 94025

EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE 1490 O’Brien Drive, Suite A, B and E Menlo Park, California 94025 THIS FIRST AMENDMENT TO LEASE (this “Amendment”) is made and entered into as of April 28, 2019 (the “Effective Date”), by and between MENLO PREPI I, LLC, a Delaware limited liability company and TPI Investors 9, LLC, a California limited liability company (collectively, “Landlord”) and F

- 2 -

EX-10.1 Exhibit 10.1 April 24, 2019 Teneobio, Inc., 1490 O’Brien Drive, Suite D Menlo Park, California 94025 Attention: Chief Financial Officer RE: CONSENT TO SUBLEASE “Building”: 1490 O’Brien Drive, Menlo Park, California “Premises”: Suite D consisting of approximately 6,230 rentable square feet in the Building; “Sublet Space”: The entire Premises consisting of Suite D containing approximately 6,

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission File N

FTSV / Forty Seven, Inc. DEFA14A DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Definitive Proxy Statement

DEF 14A 1 nc10001254x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant  o Check the appropriate box:  o Preliminary Proxy Statement  o Confidential,

FTSV / Forty Seven, Inc. S-8

S-8 As filed with the U.S. Securities and Exchange Commission on March 28, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Forty Seven, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-4065674 (State or other jurisdiction of Incorporation or organization) (I.R.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 ftsv-8k20190328.htm 8-K Q4 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdictio

Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights -- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in

Exhibit 99.1 Helping Patients Defeat Their Cancer Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights - Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in Second Quarter of 2019 – - Updated Data from Phase 1b Trial of 5F9 as a Monotherapy and in Combinati

FTSV / Forty Seven, Inc. 10-K (Annual Report)

10-K 1 ftsv-10k20181231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38554 FORTY SEVEN, IN

FTSV / Forty Seven, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

Amended and Restated Annual Bonus Plan

EX-10.1 Exhibit 10.1 FORTY SEVEN, INC. AMENDED AND RESTATED ANNUAL BONUS PLAN EFFECTIVE: JANUARY 23, 2019 1. PURPOSE The Forty Seven, Inc. Amended and Restated Annual Bonus Plan (the “Plan”) is designed to provide cash-based incentive compensation to individuals who make important contributions to the success of Forty Seven, Inc. (the “Company”). The Plan is intended to provide individuals with in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 d695796d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2019 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorp

[Forty Seven, Inc. - Joint Filing Agreement]

EX-99.1 CUSIP No. 34983P104 13D Page 22 of 24 Pages EXHIBIT 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Forty Seven, Inc. Date: January 10, 2019 CLARUS

POWER OF ATTORNEY

EX-99.2 CUSIP No. 34983P104 13D Page 24 of 24 Pages EXHIBIT 99.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert Liptak with full power to act singly, his true and lawful attorney-in-fact, with full power of substitution, to: (i) sign any and all instruments, certificates and documents that may be necessary, desira

FTSV / Forty Seven, Inc. / Clarus Lifesciences III, L.P. - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment

SC 13D/A 1 d675475dsc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Forty Seven, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 34983P104 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 12

Material Modification to Rights of Security Holders, Other Events

8-K 1 d682458d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2018 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incor

Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights -- Advanced Oncology Pipeline with FSI-189, an Anti-SIRPα Antibody; Investigational New Drug (IND) Application-Enabling Studies Expected to Begin in 2019 – -

Exhibit 99.1 Forty Seven Inc. Reports Third Quarter 2018 Financial Results and Recent Business Highlights - Advanced Oncology Pipeline with FSI-189, an Anti-SIRPα Antibody; Investigational New Drug (IND) Application-Enabling Studies Expected to Begin in 2019 – - New England Journal of Medicine Published Data from Phase 1b Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgki

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2018 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission Fil

FTSV / Forty Seven, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38554 FORTY SEVEN, INC.

SETTLEMENT AND LICENSE AGREEMENT

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Forty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business Highlights -- Presented Preliminary Data from Three Clinical Trials of 5F9 as a Monotherapy and Combination Agent -- -- Granted Fast Track Designation from the U.S. Fo

Exhibit 99.1 Forty Seven Inc. Reports Second Quarter 2018 Financial Results and Recent Business Highlights - Presented Preliminary Data from Three Clinical Trials of 5F9 as a Monotherapy and Combination Agent - - Granted Fast Track Designation from the U.S. Food and Drug Administration for 5F9 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma – - Dosed First Patient in Phase 1b Clinical Tri

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2018 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission File

FTSV / Forty Seven, Inc. 10-Q (Quarterly Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38554 FORTY SEVEN, INC.

Entry into a Material Definitive Agreement

8-K 1 d547674d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2018 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Inco

FTSV / Forty Seven, Inc. / Lightspeed Venture Partners X, L.p. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P 104 (CUSIP Number) Andrew Moley Lightspeed Venture Partners 2200 Sand Hill Road Menlo Park, CA 94025 Telephone: (650) 234-8300 (Name, Address and Telephone Number of Per

FTSV / Forty Seven, Inc. / SUTTER HILL VENTURES - SCHEDULE 13D Activist Investment

SC 13D 1 tv498329sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P 104 (CUSIP Number) Robert Yin Sutter Hill Ventures 755 Page Mill Rd., Suite #A-200 Palo Alto, CA 94304 650-493-5600 (Name, Addres

FTSV / Forty Seven, Inc. / Clarus Lifesciences III, L.P. - CLARUS LIFESCIENCES III, L.P. FORTY SEVEN, INC. -- SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Forty Seven, Inc. (Name of Issuer) Common Stock, $.0001 par value per share (Title of Class of Securities) 34983P104 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 1210, Cambridge, MA 02142 (617) 949-2200 (Name, Address and Telep

FTSV / Forty Seven, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Forty Seven, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 34983P104 (CUSIP Number) June 29, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i

Amended and Restated Certificate of Incorporation of Forty Seven, Inc.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF FORTY SEVEN, INC. Mark A. McCamish hereby certifies that: ONE: The original name of this corporation is CD47 Sciences, Inc. and the date of filing the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was October 14, 2014. TWO: He is the duly elected and acting Presi

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2018 FORTY SEVEN, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38554 47-4065674 (State or Other Jurisdiction of Incorporation) (Commission File Num

FTSV / Forty Seven, Inc. REGISTRATION STATEMENT ON FORM S-8

S-8 1 d618405ds8.htm REGISTRATION STATEMENT ON FORM S-8 As filed with the U.S. Securities and Exchange Commission on June 28, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Forty Seven, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-4065674 (State or other j

7,035,000 Shares COMMON STOCK

424B4 1 d523840d424b4.htm 424B4 Table of Contents Index to Financial Statements Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-225390 and 333-225933 PROSPECTUS 7,035,000 Shares COMMON STOCK Forty Seven, Inc. is offering 7,035,000 shares of its common stock. This is our initial public offering and no public market currently exists for our shares of common stock. Our common stock has been ap

FTSV / Forty Seven, Inc. S-1MEF

As filed with the U.S. Securities and Exchange Commission on June 27, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FORTY SEVEN, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 2834 47-4065674 (State or Other Jurisdiction of Incorporation or Organization) (Prim

FTSV / Forty Seven, Inc. CORRESP

CORRESP 1 filename1.htm Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Credit Suisse Securities (USA) LLC 11 Madison Avenue New York, New York 10010 June 25, 2018 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Forty Seven, Inc. Registration Statement on Form S-1 Registration File No. 333-225390 Dear Ladies and Gentl

FTSV / Forty Seven, Inc. CORRESP

CORRESP 1 filename1.htm FORTY SEVEN, INC. 1490 O’Brien Drive, Suite A Menlo Park, California 94025 June 25, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Ms. Suzanne Hayes, Assistant Director Ms. Dorrie Yale, Attorney Advisor Mr. Jacob Luxenburg, Staff Accountant RE: Forty Seven, Inc. Registrati

FTSV / Forty Seven, Inc. CORRESP

John T. McKenna +1 650 843 5059 [email protected] June 18, 2018 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington D.C., 20549 Attention: Dorrie Yale Jacob Luxenburg Jim Rosenberg Re: Forty Seven, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed June 7, 2018 File No. 333-225390 Ladies and Gentlemen: On behalf of Forty Se

FTSV / Forty Seven, Inc. CORRESP

CORRESP 1 filename1.htm *FOIA Confidential Treatment Request* Confidential Treatment Requested by Forty Seven, Inc. in connection with Registration Statement on Form S-1 filed on June 1, 2018 JOHN T. MCKENNA +1 650 843 5059 [email protected] June 8, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, DC 20549 Attn: Ms. Suzann

FTSV / Forty Seven, Inc. DRSLTR

John T. McKenna +1 650 843 5059 [email protected] May 14, 2018 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Dorrie Yale Re: Forty Seven, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted on April 30, 2018 CIK No. 0001667633 Ladies and Gentleman: On behalf of Forty Seven, Inc. (“Forty Seven” or the “Company”), we are sub

FTSV / Forty Seven, Inc. DRSLTR

DRSLTR 1 filename1.htm John T. McKenna +1 650 843 5059 [email protected] April 30, 2018 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Dorrie Yale Re: Forty Seven, Inc. Draft Registration Statement on Form S-1 Submitted March 23, 2018 CIK No. 0001667633 Ladies and Gentleman: On behalf of Forty Seven, Inc. (“Forty Seven” or the “Company”), we subm